TANZANIA is among countries expected to benefit from the upcoming rollout of injectable lenacapavir for HIV prevention, following a landmark recommendation by the World Health Organization (WHO).

In a session titled, Better meeting the needs of people living with HIV, health experts reminded us that science, care, and human rights must move together if we are to achieve real change.

Newborns exposed to HIV during pregnancy or birth should receive preventive antiretroviral medication immediately after ...

The World Health Organisation (WHO) has raised concern over the stagnation of global HIV prevention efforts, announcing ...

A decade ago, the global community established the goal to end AIDS as a public health threat by 2030 through reducing new HIV infections and AIDS-related deaths by 90% from 2010 levels.1 Progress has ...

A monthly pill would add to the growing number of choices for HIV preexposure prophylaxis, which is now seen as the best hope ...

Lenacapavir, new twice-yearly HIV injection, raises hope for pill-weary patients. Discordant couples, sex workers hail ‘game ...

Lenacapavir has been incredibly promising in trials and now the World Health Organisation have officially recommended the drug for HIV prevention. Smitha Mundasad explains the difference this ...

An investigational once-weekly oral antiretroviral therapy (ART) combination effectively maintained viral suppression in ...

The money is not nearly enough to put two to four million people per year in South Africa on the lenacapavir jab, and even if it were, the country’s health system won’t be able to roll out the ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

The global recommendation – issued Monday at the International AIDS Conference in Kigali, Rwanda – comes about a month after ...